The Center for Research & Clinical Trials:
The Eye Institute for Medicine & Surgery is currently partnered with Clearside Biomedical for the TOPAZ research study for people who have experienced sudden vision loss due to Retinal Vein Occlusion (RVO). Read more below to find out if you might be a candidate.
Who is eligible to participate in the TOPAZ Study?
To pre-qualify for this study, you must meet the following criteria:
- Be at least 18 years of age
- Have been diagnosed with RVO in your eye within 6 months of beginning the study
- Have not received treatment for RVO
In addition, reimbursement for study-related time and travel may be provided.
What Will Happen During the TOPAZ Study?
If you are eligible for this study, you will be randomly assigned to 1 of 4 treatment groups. Two groups will receive injections of one of the drugs that reduces excess eye fluid and the investigational drug. The other two groups will receive injections of one of the drugs that reduces excess eye fluid and have sham procedures performed. You have an equal chance of being assigned to any of the 4 treatments groups.
You will visit The Center for Clinical Trials at The Eye Institute about every 4 weeks to receive at least one injection. During your study clinic visits, doctors and the study staff will evaluate your health and progress through various tests and assessments. Your total study participation will last approximately 50 weeks and includes up to 12 study clinic visits.
What Are the Benefits and Risks Related to the Topaz Study?
While it is possible you could benefit from participating in this study, that cannot be guaranteed. It is also possible you could experience a side effect while in this study. The study staff will review the full list of risks and side effects with you before you join the study.
Because research studies can affect your health and safety, you will be monitored while you are in this study. The sponsor of this study was required to design a protocol, which explains all study procedures in detail. An independent review board responsible for participant safety reviewed this protocol and requires that it be followed exactly.
Ready to Learn More?
Call us at 321-722-4443, wait for the recording to begin and then dial *136 to speak with a study coordinator.